AlphaRx Inc. announced today a major product launch in China. Through AlphaRx International Holdings (AIH), its Hong Kong affiliate, AlphaRx will launch Indaflex in 2008.
Already a successful topical arthritis relief product in Mexico, AIH is building a plant in China to meet the expected demand. AIH will also produce Dicloflex(TM), an eye-drop formula used to treat ocular inflammation and pain, as well as Vansolin(TM) and Zysolin(TM), used for serious infections such as lung inflammation and nosocomial pneumonia, for the rapidly growing Chinese market.
Michael Lee, chairman of AlphaRx, said, "this is the beginning of a major push into the world's biggest market. And with a permanent presence in Hong Kong through AIH, we are here to succeed over the short- and long-term."
AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The company also discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and neurodegenerative diseases.